Newron Pharmaceuticals S.p.A. (“Newron”), a biopharmaceutical
company focused on the development of novel therapies for patients
with diseases of the central nervous system (CNS) and pain, today
announced its support of this year’s Rare Disease Day® - which
takes place worldwide on the last day of February each year –
and the Rett community to raise awareness of the importance of
research for rare diseases. United together, patients and
caregivers, researchers and advocacy groups are working in common
to elevate understanding and improve the lives of those impacted by
rare diseases.
“We are proud to continue our support of NORD (The National
Organization for Rare Disorders in the USA) and EURORDIS (the
European Organization for Rare Diseases) as they work to increase
awareness for rare diseases and the unique challenges of those
affected,” said Dennis Dionne, Vice President Commercial Affairs,
Newron. “We are particularly honored to support groups such as
Rettsyndrome.org which is dedicated to improving the lives of girls
living with Rett syndrome.”
Burden of Disease StudyAs part of its commitment to the
rare disease patient community, Newron is partnering with the
global Rett community to work on the first Burden of Disease (BOD)
study. The study aims to deliver data and analytics to quantify the
physical, emotional and financial challenges of Rett syndrome.
These learnings can help identify improved intervention programs
and services designed to complement the Rett care pathway.
Learn MoreView a video on Rett syndrome here.
STARS StudyNewron has also initiated the Sarizotan
Treatment of Apneas in Rett Syndrome (STARS) study, a potentially
pivotal clinical study to evaluate the efficacy, safety and
tolerability of sarizotan in patients with Rett syndrome suffering
from respiratory symptoms. Among the core symptoms of Rett,
breathing disturbances may affect the whole person body; they can
have a marked effect on biochemistry, influence emotions,
circulation and digestive function as well as musculoskeletal
structures in the respiratory process.
About Rare Disease Day®Rare
Disease Day takes place on the last day of February each year,
thus on February 28, 2017. The main objective of Rare Disease
Day is to raise awareness amongst the general public and
decision-makers about rare diseases and their impact on
patients' lives. The campaign targets primarily the general
public and also seeks to raise awareness amongst policy
makers, public authorities, industry representatives,
researchers, health professionals and anyone who has a genuine
interest in rare diseases. The campaign started as a European event
and has progressively become a world phenomenon, with
the USA joining in 2009 and participants in over 80
countries throughout the world in 2016.
In the United States, the National Organization for Rare
Disorders (NORD) promotes and celebrates Rare Disease Day. For more
information about Rare Disease Day in the U.S., please visit
http://www.rarediseaseday.us. For information about global
activities, please visit www.rarediseaseday.org.
About Rare DiseasesThe
European Union considers a disease as rare when it affects fewer
than 5 in 10,000 citizens. According to EURORDIS, over 6,000
different rare diseases have been identified to date, affecting
over 60 million people in Europe and the USA alone. Due to the low
prevalence of each disease, medical expertise is rare, knowledge is
scarce, care offering inadequate and research limited. Despite
their great overall number, rare disease patients are the orphans
of health systems, often denied diagnosis, treatment and the
benefits of research.
About Rett SyndromeRett
syndrome is a severe neurodevelopmental disorder primarily
affecting females, with an estimated prevalence ranging from one in
10,000 to one in 20,000 females. There are no approved treatments
available. Rett syndrome is characterized by a loss of acquired
fine and gross motor skills and the development of neurological,
cognitive and autonomic dysfunction, which leads to loss of ability
to conduct daily life activities, walk or communicate. Rett
syndrome also is associated with a reduced life expectancy.
Approximately 25 percent of the deaths in patients with Rett
syndrome are possibly related to multiple cardio-respiratory
dysrhythmias that result from brain stem immaturity and autonomic
failure. More than 95 percent of these patients have a random
mutation in the MECP2 gene. Episodes of apnea, hyperventilation and
disordered breathing are found in approximately 70 percent of
patients with Rett syndrome at some stage of their life. For more
information on Rett Syndrome, visit www.rettsyndrome.org.
About Newron
PharmaceuticalsNewron (SIX: NWRN) is a biopharmaceutical
company focused on the development of novel therapies for patients
with diseases of the central nervous system (CNS) and pain. The
Company is headquartered in Bresso near Milan, Italy.
Xadago® (safinamide) has received marketing authorization
for the treatment of Parkinson’s disease in the European Union and
Switzerland and is commercialized by Newron’s partner Zambon. US
WorldMeds holds the commercialization rights in the US. Meiji Seika
has the rights to develop and commercialize the compound in Japan
and other key Asian territories. In addition to Xadago® for
Parkinson’s disease, Newron has a strong pipeline of promising
treatments for rare disease patients at various stages of clinical
development, including sarizotan for patients with Rett syndrome
and ralfinamide for patients with specific rare pain indications.
Newron is also developing Evenamide as the potential first add-on
therapy for the treatment of patients with positive symptoms of
schizophrenia. www.newron.com
Important NoticesThis document contains forward-looking
statements, including (without limitation) about (1) Newron’s
ability to develop and expand its business, successfully complete
development of its current product candidates and current and
future collaborations for the development and commercialisation of
its product candidates and reduce costs (including staff costs),
(2) the market for drugs to treat CNS diseases and pain conditions,
(3) Newron’s anticipated future revenues, capital expenditures and
financial resources, and (4) assumptions underlying any such
statements. In some cases these statements and assumptions can be
identified by the fact that they use words such as “will”,
“anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”,
“believe”, “target”, and other words and terms of similar meaning.
All statements, other than historical facts, contained herein
regarding Newron's strategy, goals, plans, future financial
position, projected revenues and costs and prospects are
forward-looking statements.
By their very nature, such statements and assumptions involve
inherent risks and uncertainties, both general and specific, and
risks exist that predictions, forecasts, projections and other
outcomes described, assumed or implied therein will not be
achieved. Future events and actual results could differ materially
from those set out in, contemplated by or underlying the
forward-looking statements due to a number of important factors.
These factors include (without limitation) (1) uncertainties in the
discovery, development or marketing of products, including without
limitation negative results of clinical trials or research projects
or unexpected side effects, (2) delay or inability in obtaining
regulatory approvals or bringing products to market, (3) future
market acceptance of products, (4) loss of or inability to obtain
adequate protection for intellectual property rights, (5) inability
to raise additional funds, (6) success of existing and entry into
future collaborations and licensing agreements, (7) litigation, (8)
loss of key executive or other employees, (9) adverse publicity and
news coverage, and (10) competition, regulatory, legislative and
judicial developments or changes in market and/or overall economic
conditions.
Newron may not actually achieve the plans, intentions or
expectations disclosed in forward-looking statements, and
assumptions underlying any such statements may prove wrong.
Investors should therefore not place undue reliance on them. There
can be no assurance that actual results of Newron's research
programmes, development activities, commercialisation plans,
collaborations and operations will not differ materially from the
expectations set out in such forward-looking statements or
underlying assumptions.
Newron does not undertake any obligation to publicly update or
revise forward-looking statements except as may be required by
applicable regulations of the SIX Swiss Exchange, where the shares
of Newron are listed.
This document does not contain or constitute an offer or
invitation to purchase or subscribe for any securities of Newron,
and no part of it shall form the basis of or be relied upon in
connection with any contract or commitment whatsoever.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170221006083/en/
MediaNewronStefan Weber, +39 02 6103 46
26CEOpr@newron.comorUK/EuropeFTI ConsultingJulia Phillips,
+44 (0)20 3727 1000orSwitzerlandIRF CommunicationsMartin
Meier-Pfister, +41 43 244 81 40orGermanyMC Services AGAnne
Hennecke, +49 211 52925222orU.S.LaVoieHealthScienceBeth
Kurth, +1-617-374-8800, Ext. 106orInvestors and
analystsNewronStefan Weber, +39 02 6103 46
26CEOpr@newron.comorUK/EuropeFTI ConsultingJulia Phillips,
+44 (0)20 3727 1000orGermany/Continental EuropeMC Services
AGAnne Hennecke, +49 211
52925222orU.S.LaVoieHealthScienceBeth Kurth,
+1-617-374-8800, Ext. 106